Dr Andy Green's Outputs (243)

Cell division cycle 6 (CDC6) is an independent prognostic biomarker in breast cancer (2024)
Journal Article
Kariri, Y. A., Alsaleem, M., Alhatlani, B. Y., Al-Kawaz, A., Mongan, N. P., Green, A. R., & Rakha, E. A. (2024). Cell division cycle 6 (CDC6) is an independent prognostic biomarker in breast cancer. Pathology, https://doi.org/10.1016/j.pathol.2024.09.006

Cell division cycle 6 (CDC6) is a cell cycle protein involved in cell cycle control, DNA replication and cancer cell apoptosis. This study investigated the prognostic value of CDC6 in breast cancer (BC) utilising large well characterised cohorts of e... Read More about Cell division cycle 6 (CDC6) is an independent prognostic biomarker in breast cancer.

Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer (2024)
Journal Article
Bhattarai, S., Rupji, M., Chao, H.-P., Xu, Q., Saini, G., Rida, P., Aleskandarany, M. A., Green, A. R., Ellis, I. O., Janssen, E. A., Jonsdottir, K., Rakha, E., Kowalski-Mueggen, J., & Aneja, R. (2024). Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer. BJC Reports, 2(1), Article 87. https://doi.org/10.1038/s44276-024-00097-z

Background
Ki67 index (KI) and mitotic index (MI) are proliferation markers with established prognostic value in breast carcinomas. While KI is evaluated immunohistochemically and reported as a percentage, MI is determined visually and reflects tota... Read More about Cell cycle traverse rate predicts long-term outcomes in a multi-institutional cohort of patients with triple-negative breast cancer.

Hydroxyacid Oxidase 1, a Glutamine Metabolism-Associated Protein, Predicts Poor Patient Outcome in Luminal Breast Cancer (2024)
Journal Article
Erkan, B., MacIntyre, S., Brown, C., Fakroun, A., Lashen, A. G., Mongan, N. P., Ellis, I. O., Rakha, E. A., & Green, A. R. (2024). Hydroxyacid Oxidase 1, a Glutamine Metabolism-Associated Protein, Predicts Poor Patient Outcome in Luminal Breast Cancer. International Journal of Molecular Sciences, 25(21), Article 11572. https://doi.org/10.3390/ijms252111572

Breast cancer (BC), which remains the most prevalent malignancy among women, is characterised by significant heterogeneity across its molecular subtypes. Oestrogen receptor-positive (ER+) (luminal) BC represents approximately 75% of cases, and despit... Read More about Hydroxyacid Oxidase 1, a Glutamine Metabolism-Associated Protein, Predicts Poor Patient Outcome in Luminal Breast Cancer.

Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer (2024)
Journal Article
Lashen, A. G., Toss, M. S., Rutland, C. S., Green, A. R., Mongan, N. P., & Rakha, E. (2024). Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer. Pathobiology, https://doi.org/10.1159/000540790

Introduction: Minichromosome maintenance complex component 7 (MCM7) plays an essential role in proliferation and DNA replication of cancer cells. However, the expression and prognostic significance of MCM7 in breast cancer (BC) remain to be defined.... Read More about Prognostic and clinical significance of the proliferation marker MCM7 in breast cancer.

The role of the ALKBH5 RNA demethylase in invasive breast cancer (2024)
Journal Article
Woodcock, C. L., Alsaleem, M., Toss, M. S., Lothion-Roy, J., Harris, A. E., Jeyapalan, J. N., Blatt, N., Rizvanov, A. A., Miftakhova, R. R., Kariri, Y. A., Madhusudan, S., Green, A. R., Rutland, C. S., Fray, R. G., Rakha, E. A., & Mongan, N. P. (2024). The role of the ALKBH5 RNA demethylase in invasive breast cancer. Discover Oncology, 15(1), Article 343. https://doi.org/10.1007/s12672-024-01205-8

Background: N6-methyladenosine (m6A) is the most common internal RNA modification and is involved in regulation of RNA and protein expression. AlkB family member 5 (ALKBH5) is a m6A demethylase. Given the important role of m6A in biological mechanism... Read More about The role of the ALKBH5 RNA demethylase in invasive breast cancer.

Stromal lymphocytes are associated with upgrade of B3 breast lesions (2024)
Journal Article
Kader, T., Provenzano, E., Jayawardana, M. W., Hendry, S., Pang, J.-M., Elder, K., Byrne, D. J., Tjoeka, L., Frazer, H. M., House, E., Jayasinghe, S. I., Keane, H., Murugasu, A., Rajan, N., Miligy, I., Toss, M., Green, A., Rakha, E., Fox, S. B., Mann, B., …Gorringe, K. L. (2024). Stromal lymphocytes are associated with upgrade of B3 breast lesions. Breast Cancer Research, 26, Article 115

Various histopathological, clinical and imaging parameters have been evaluated to identify a subset of women diagnosed with lesions with uncertain malignant potential (B3 or BIRADS 3/4A lesions) who could safely be observed rather than being treated... Read More about Stromal lymphocytes are associated with upgrade of B3 breast lesions.

Nottingham Prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: A validation study (2024)
Journal Article
Lashen, A. G., Toss, M., Miligy, I., Rewcastle, E., Kiraz, U., Janssen, E. A. M., Green, A. R., Quinn, C., Ellis, I., & Rakha, E. (2024). Nottingham Prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: A validation study. Histopathology, 85(3), 468-477. https://doi.org/10.1111/his.15234

Aims
In this study, we validate the use of Nottingham Prognostic x (NPx), consisting of tumour size, tumour grade, progesterone receptor (PR) and Ki67 in luminal BC.

Materials and methods
Two large cohorts of luminal early-stage BC (n = 2864) we... Read More about Nottingham Prognostic x (NPx): a risk stratification tool in ER-positive HER2-negative breast cancer: A validation study.

ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Estrogen Receptor Positive Breast Cancer (2024)
Journal Article
Patel, R., Alfarsi, L. H., El-Ansari, R., Masisi, B. K., Erkan, B., Fakroun, A., Ellis, I. O., Rakha, E. A., & Green, A. R. (in press). ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Estrogen Receptor Positive Breast Cancer. Pathobiology, https://doi.org/10.1159/000539564

Purpose: ATF4, a stress-responsive transcription factor that upregulates adaptive genes, is a potential prognostic marker and modulator of glutamine metabolism in breast cancer. However, its exact role remains to be elucidated.

Methods: ATF4 expre... Read More about ATF4 as a Prognostic Marker and Modulator of Glutamine Metabolism in Estrogen Receptor Positive Breast Cancer.

The characteristics and prognostic significance of histone H1 expression in breast cancer (2024)
Journal Article
Lashen, A. G., Almalki, N., Toss, M., Mirza, S., Malki, M. I., Rutland, C. S., Jeyapalan, J. N., Green, A. R., Mongan, N. P., Madhusudan, S., & Rakha, E. A. (2024). The characteristics and prognostic significance of histone H1 expression in breast cancer. Pathology, 56(6), 826-833. https://doi.org/10.1016/j.pathol.2024.03.012

Histone H1 (H.H1) is involved in chromatin organisation and gene regulation and is overexpressed in many malignant tumours, including breast cancer (BC). This study proposed and evaluated the prognostic role of H.H1 expression in BC.

H.H1 mRNA exp... Read More about The characteristics and prognostic significance of histone H1 expression in breast cancer.

Tripartite Motif Containing 2, a glutamine metabolism-associated protein, predicts poor patient outcome in triple negative breast cancer treated with chemotherapy (2024)
Journal Article
Masisi, B. K., El Ansari, R., Alfarsi, L., Fakroun, A., Erkan, B., Ibrahim, A., Toss, M., Ellis, I. O., Rakha, E. A., & Green, A. R. (2024). Tripartite Motif Containing 2, a glutamine metabolism-associated protein, predicts poor patient outcome in triple negative breast cancer treated with chemotherapy. Cancers, 16(11), Article 1949. https://doi.org/10.3390/cancers16111949

Background: Breast cancer (BC) remains heterogeneous in terms of prognosis and response to treatment. Metabolic reprogramming is a critical part of oncogenesis and a potential therapeutic target. Glutaminase (GLS), which generates glutamate from glut... Read More about Tripartite Motif Containing 2, a glutamine metabolism-associated protein, predicts poor patient outcome in triple negative breast cancer treated with chemotherapy.

Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype (2024)
Journal Article
Makhlouf, S., Atallah, N. M., Polotto, S., Lee, A. H., Green, A. R., & Rakha, E. A. (2024). Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype. Cancers, 16(10), Article 1893. https://doi.org/10.3390/cancers16101893

Background: Invasive lobular carcinoma (ILC), the most common special type of breast cancer (BC), has unique clinical behaviour and is different from invasive ductal carcinoma of no special type (IDC-NST). However, ILC further comprises a diverse gro... Read More about Deciphering the Clinical Behaviour of Invasive Lobular Carcinoma of the Breast Defines an Aggressive Subtype.

Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value (2024)
Journal Article
Alhudiri, I., Nolan, C., Ellis, I., Elzagheid, A., Green, A., & Chapman, C. (2024). Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value. Breast Cancer Research and Treatment, 206(1), 143-153. https://doi.org/10.1007/s10549-024-07293-y

Purpose
Cathepsin D is a proteolytic enzyme that is normally localized in the lysosomes and is involved in the malignant progression of breast cancer. There are conflicting results regarding Cathepsin D significance as prognostic and predictor marke... Read More about Expression of Cathepsin D in early-stage breast cancer and its prognostic and predictive value.

The amino acid transporter SLC7A11 expression in breast cancer (2023)
Journal Article
Nath, P., Alfarsi, L. H., El-Ansari, R., Masisi, B. K., Erkan, B., Fakroun, A., Ellis, I. O., Rakha, E. A., & Green, A. R. (2024). The amino acid transporter SLC7A11 expression in breast cancer. Cancer Biology and Therapy, 25(1), Article 2291855. https://doi.org/10.1080/15384047.2023.2291855

Breast cancer (BC), characterized by its diverse molecular profiles and clinical outcomes, presents a significant challenge in the development of effective therapeutic strategies. Metabolic reprogramming, a defining characteristic of cancer, has emer... Read More about The amino acid transporter SLC7A11 expression in breast cancer.

Unravelling transcriptomic complexity in breast cancer through modulation of DARPP-32 expression and signalling pathways (2023)
Journal Article
Saidy, B., Vasan, R., Durant, R., Greener, M.-R., Immanuel, A., Green, A. R., Rakha, E., Ellis, I., Ball, G., Martin, S. G., & Storr, S. J. (2023). Unravelling transcriptomic complexity in breast cancer through modulation of DARPP-32 expression and signalling pathways. Scientific Reports, 13(1), Article 21163. https://doi.org/10.1038/s41598-023-48198-y

DARPP-32 is a key regulator of protein-phosphatase-1 (PP-1) and protein kinase A (PKA), with its function dependent upon its phosphorylation state. We previously identified DKK1 and GRB7 as genes with linked expression using Artificial Neural Network... Read More about Unravelling transcriptomic complexity in breast cancer through modulation of DARPP-32 expression and signalling pathways.

The expression of high mobility group protein 3 (HMGB3) in breast cancer with emphasis on its role in lymphovascular invasion (2023)
Journal Article
Aljohani, A., Alsaeed, S., Toss, M., Raafat, S., GREEN, A., & Rakha, E. (2023). The expression of high mobility group protein 3 (HMGB3) in breast cancer with emphasis on its role in lymphovascular invasion. American Journal of Cancer Research, 13(11), 5334–5351

Lymphovascular invasion (LVI) is a common phenomenon in breast cancer (BC), and it is correlated to poor outcome. However, the biomarkers that influence the development of LVI remain to be defined. Through rigorous bioinformatics analyses, high mobil... Read More about The expression of high mobility group protein 3 (HMGB3) in breast cancer with emphasis on its role in lymphovascular invasion.

Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression (2023)
Journal Article
Atallah, N. M., Haque, M., Quinn, C., Toss, M. S., Makhlouf, S., Ibrahim, A., Green, A. R., Alsaleem, M., Rutland, C. S., Allegrucci, C., Mongan, N. P., & Rakha, E. (2023). Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression. European Journal of Cancer, 195, Article 113371. https://doi.org/10.1016/j.ejca.2023.113371

Background: Breast cancer (BC) expressing low levels of human epidermal growth factor receptor 2 (HER2 Low) is an emerging category that needs further refining. This study aims to provide a comprehensive clinico-pathological and molecular profile of... Read More about Characterisation of luminal and triple-negative breast cancer with HER2 Low protein expression.

Obesity-associated changes in molecular biology of primary breast cancer (2023)
Journal Article
Nguyen, H.-L., Geukens, T., Maetens, M., Aparicio, S., Bassez, A., Borg, A., Brock, J., Broeks, A., Caldas, C., Cardoso, F., De Schepper, M., Delorenzi, M., Drukker, C. A., Glas, A. M., Green, A. R., Isnaldi, E., Eyfjörð, J., Khout, H., Knappskog, S., Krishnamurthy, S., …Desmedt, C. (2023). Obesity-associated changes in molecular biology of primary breast cancer. Nature Communications, 14, Article 4418. https://doi.org/10.1038/s41467-023-39996-z

Obesity is associated with an increased risk of developing breast cancer (BC) and worse prognosis in BC patients, yet its impact on BC biology remains understudied in humans. This study investigates how the biology of untreated primary BC differs acc... Read More about Obesity-associated changes in molecular biology of primary breast cancer.

The clinical and biological significance of estrogen receptor-low positive breast cancer (2023)
Journal Article
Makhlouf, S., Althobi, M., Toss, M., Muftah, A. A., Mongan, N. P., Lee, A. H. S., Green, A. R., & Rakha, E. A. (2023). The clinical and biological significance of estrogen receptor-low positive breast cancer. Modern Pathology, 36(10), Article 100284. https://doi.org/10.1016/j.modpat.2023.100284

Estrogen Receptor (ER) status in breast cancer (BC) is determined using immunohistochemistry (IHC) with nuclear expression in ≥1% of cells defined as ER-positive. BC with 1-9% expression (ER-low positive), is a clinically and biologically unique subg... Read More about The clinical and biological significance of estrogen receptor-low positive breast cancer.

Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer (2023)
Journal Article
Lashen, A. G., Toss, M. S., Wootton, L., Green, A. R., Mongan, N. P., Madhusudan, S., & Rakha, E. (2023). Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer. Histopathology, 83(3), 414-425. https://doi.org/10.1111/his.14960

Background: Polo-like kinase-1 (PLK1) plays a crucial role in cell cycle progression,and it is considered a potential therapeutic target in many cancers. Although the role of PLK1 is well established in triple negative breast cancer (TNBC) as an onco... Read More about Characteristics and prognostic significance of polo-like kinase-1 (PLK1) expression in breast cancer.

Assessment of the Androgen Receptor in Older Women with Primary Breast Cancer: Association with a Panel of Biomarkers and Breast Cancer Specific Survival (2023)
Journal Article
Kalvala, J., Parks, R. M., Abdi, J., Green, A. R., & Cheung, K. L. (2023). Assessment of the Androgen Receptor in Older Women with Primary Breast Cancer: Association with a Panel of Biomarkers and Breast Cancer Specific Survival. Advances in Therapy, https://doi.org/10.1007/s12325-023-02504-2

Introduction
Breast cancer in older women tends to have more favourable biology, compared to younger women. Androgen receptor (AR) is significant for breast tumour carcinogenesis; however, the role of AR in older women has not been fully explored.... Read More about Assessment of the Androgen Receptor in Older Women with Primary Breast Cancer: Association with a Panel of Biomarkers and Breast Cancer Specific Survival.